1. . Atlas: multiple sclerosis resources in the world. Geneva: World Health Organization; 2008.
2. , , The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182–91.
3. , , Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281–300.
4. , , , et al., eds. McAlpine's multiple sclerosis. London: Churchill Livingstone; 2006.
5. , , , et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(Pt 11):2705–12.
6. , , , et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 2008;14:1068–75.
7. , Progressive multiple sclerosis. Semin Immunopathol 2009;31:455–65.
8. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52.
9. , , , Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry 2002;73:154–9.
10. , , , , Relationship between neurological and urological status in patients with multiple sclerosis. J Urol 1984;132:499–502.
11. , , Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:245–50.
12. , , , et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:470–7.
13. , , , Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430–8.
14. , , Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126(Pt 4):770–82.
15. , , , , Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology 2007;68:1971–8.
16. , , , What drives quality of life in multiple sclerosis? QJM 2004;97:671–6.
17. , , , et al. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 1999;80(4):437–41.
18. , , , , The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915–28.
19. , , , , Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995;154:169–73.
20. , , , et al. Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters? Spinal Cord 1997;35:33–6.
21. , , Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002;11:560–5.
22. , , , Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006;25:337–48.
23. , , , Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 1997;11:211–9.
24. , , The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med 1994;87:681–2.
25. , , , , Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001;20:138–43.
26. , , , et al. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol 1991;145:1219–24.
27. , , Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 1994;151:946–50.
28. , , , , Fate of the upper urinary tract in multiple sclerosis. Neurourol Urodyn 1995;14:81–5.
29. , , , et al. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil 1998;79:255–7.
30. , , , et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler 2009;15:379–84.
31. , , , et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995;153:1114–6.
32. , , , et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98.
33. , , Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003;17:42–7.
34. , , , et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989–94.
35. , Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135:966–8.
36. , , , , Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004;27:214–8.
37. , , , et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021–8.
38. , , , et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317–26.
39. , , , , Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005;112:1–5.
40. , , , A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998;81:215–8.
41. , , , et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425–33.
42. , , , et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636–41.
43. , , , Randomised controlled trial of Sativex to treat detrusor over activity in multiple sclerosis. Multiple Sclerosis 2010;submitted.
44. , , , et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998;17:513–23.
45. , , , et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26:358–63.
46. , , , et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196–200.
47. , , , et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335–40.
48. , , , et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
49. , , , et al. Sustained and significant quality of life improvement after intra-detrusor botulinum toxin type A injections for neurogenic detrusor overactivity secondary to multiple sclerosis. Br J Urol [Presentation] 2009;103:37.
50. , Successful treatment with intradetrusor botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol 2006;50:806–9.
51. , , , et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613–8.
52. , , . Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007;197:96.e1–5.
53. , , , et al. Quality of life assessment in patients who undergo sacral neuromodulation implantation for urge incontinence: an additional tool for evaluating outcome. J Urol 2001;166:2277–80.
54. , , , , Groupe d'Etudes de Neuro-Urologie de Langue Francaise (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Prog Urol 2007;17:631–3.
55. , , , et al. Guidelines on neurogenic lower urinary tract dysfunction. Prog Urol 2007;17:687–99.
56. , , , , Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008;46:622–6.
57. , , , et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125(Pt 5):952–60.
58. , , , et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 1998;159:1881–4.
59. , , , Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. J Urol 2008;180:2592–8.
60. , Colonic and anorectal dysfunction associated with multiple sclerosis. Am J Gastroenterol 1989;84:587–95.
61. , , Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 1990;98:1538–42.
62. , , , et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995;242:105–8.
63. , , Disturbances of ano-rectal function in multiple sclerosis. J Neurol 1996;243:445–51.
64. , , , Bladder, bowel and sexual dysfunction in patients with multiple sclerosis – a cohort study. Scand J Urol Nephrol 1996;179(Suppl):61–6.
65. , , , et al. Anorectal dysfunction in multiple sclerosis. Mult Scler 2006;12:215–8.
66. , , , Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001;13:441–8.
67. . Management of multiple sclerosis in primary and secondary care. London: NICE, 2003.
68. , Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009;3:417–23.
69. , , Gastrointestinal complications of spinal cord injury. Spine (Phila Pa 1976) 1981;6:538–44.
70. , , , et al. Colonic dysfunction in patients with thoracic spinal cord injury. Gastroenterology 1984;86:287–94.
71. , , Colonic myoelectric activity in persons with spinal cord injury. Dig Dis Sci 1985;30:295–300.
72. , , Anorectal function in incontinent patients with cerebrospinal disease. Gastroenterology 1990;99:1372–9.
73. , , , et al. Paradoxical puborectalis contraction is a feature of constipation in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:31–5.
74. , , , et al. Radiopaque markers transit and anorectal manometry in 16 patients with multiple sclerosis and urinary bladder dysfunction. Dis Colon Rectum 1987;30:95–100.
75. , , , , Multiple sclerosis assessment of colonic and anorectal function in the presence of faecal incontinence. Int J Colorectal Dis 1993;8:220–4.
76. , Evidence of reduced rectal compliance in constipated patients with multiple sclerosis. In: , ed. Association of Coloproctology of Great Britain and Ireland, Harrogate8–11/06/2009(Poster).
77. , , , , Intestinal transit studied with radiopaque markers in patients with multiple sclerosis. Radiol Med 1992;83:428–30.
78. , , , , Colonic dysfunction in multiple sclerosis. Gastroenterology 1982;83:1002–7.
79. , , , , Colonometry, cystometry, and evoked potentials in multiple sclerosis. Arch Neurol 1982;39:698–701.
80. , , , , The conus demyelination syndrome in multiple sclerosis. Acta Neurol Scand 1984;69:80–9.
81. , , , et al. Pelvic floor function in multiple sclerosis. Gut 1994;35:388–90.
82. , , Parity as a factor in incontinence in multiple sclerosis. Arch Neurol 1987;44:504–8.
83. , , Electrophysiology of motor pathways for sphincter control in multiple sclerosis. J Neurol Neurosurg Psychiatry 1990;53:955–60.
84. , Motor conduction velocity in the human spinal cord: slowed conduction in multiple sclerosis and radiation myelopathy. J Neurol Neurosurg Psychiatry 1985;48:1135–9.
85. , , , Proctographic features of anismus. Radiology 1995;197:679–82.
86. , , , , Impairment of defecation in young women with severe constipation. Gastroenterology 1986;90:53–60.
87. , Abnormal visceral autonomic innervation in neurogenic faecal incontinence. Gut 1993;34:215–21.
88. , , , et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;69:240–3.
89. , , , Successful biofeedback in patients with multiple sclerosis is related to disability and mood factors more than anorectal physiology variables. Gastroenterology 2009;136(5 Suppl 1):A380.
90. , , , et al. Manometric correlations of anorectal dysfunction and biofeedback outcome in patients with multiple sclerosis. Mult Scler 2008;14:237–42.
91. , Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002;15:271–8.
92. , , , et al. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 2008;14:1131–6.
93. , , , Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001;7:417–21.
94. , , , et al. Sexual dysfunction in multiple sclerosis: a 2 year follow-up study. J Neurol Sci 2001;187:1–5.
95. , , , et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5:428–31.
96. , , , Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 1994;117(Pt 6):1303–10.
97. , Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehab 1984;65:125–8.
98. , , , Erectile dysfunction in multiple sclerosis. Neurol 1988;38:1366–71.
99. , , , et al. Value of nocturnal penile tumescence and rigidity (NPTR) recording in impotent patients with multiple sclerosis. Int J Impot Res 1996;8:241–5.
100. , , , et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5:428–31.
101. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand 1969;45:166–82.
102. , Ejaculatory failure. World J Urol 1993;11:89–95.
103. , , , et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001;7(4):231–5.
104. , , Correlates of sexual dysfunction in men and women with multiple sclerosis. J Neurosci Nurs 2008;40:312–7.
105. , , , et al. Sexual dysfunction in newly diagnosed multiple sclerosis women. Mult Scler 2008;14:561–3.
106. , Episodic hyperlibidinism in multiple sclerosis. Mult Scler 2001;7:67–70.
107. , , Hypersexuality, fetishism and multiple sclerosis. Br J Psychiatry 1991;158:280–1.
108. , , Acquired sexual paraphilia in patients with multiple sclerosis. Arch Neurol 2002;59:1006–10.
109. , , , et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urol 1997;49:822–30.
110. , , , et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
111. , , The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1–20.
112. , , , et al. Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Mult Scler 2007;13:95–105.
113. , , , et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005May;76(5):700–5.
114. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009;181:252–8.
115. , , , et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2008;179(5 Suppl):S92–4.
116. , , , , An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271–5.
117. Yohimbine in the treatment of erectile disorder. Br J Clin Pract 1994;48:133–6.
118. , , Yohimbine: a clinical review. Pharmacol Ther 2001;91:215–43.
119. , , , , Midodrine improves orgasm in spinal cord-injured men: the effects of autonomic stimulation. J Sex Med 2008;5:2935–41.
120. , , , , Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189–93.
121. , Sexual dysfunction associated with intrathecal baclofen use: a report of two cases. J Spinal Cord Med 2008;31:103–5.
122. , , , Baclofen-induced sexual dysfunction. Neurology 2006;67:1097–8.
123. PLISSIT Therapy. In: , ed. Handbook of innovative psychotherapies. New York: Wiley and Sons; 1981:626–39.
124. , , Persistent motor deficits predict long-term bladder dysfunction in children following acute transverse myelitis. J Urol 2008;180 (4 Suppl):1774–7.
125. , , , et al. Lower urinary tract dysfunction in central pontine myelinolysis: possible contribution of the pontine micturition centre. Eur J Neurol 2005;12:812–3.
126. , , , Micturitional disturbance in acute disseminated encephalomyelitis (ADEM). J Auton Nerv Syst 1996;60:200–5.
127. , , , , Lower urinary tract dysfunction in acute disseminated encephalomyelitis. Mult Scler 2009;15:1118–22.
128. , , , et al. Meningitis-retention syndrome. An unrecognized clinical condition. J Neurol 2005;252:1495–9.
129. , , , et al. Micturitional disturbance in a patient with adrenomyeloneuropathy (AMN). Neurourol Urodyn 1998;17:207–12.
130. , , , Brachial diplegia in central pontine myelinolysis. J Neurol 1985;231:345–6.
131. , , , , Urinary dysfunction in patients with systemic lupus erythematosis. Neurourol Urodyn 2003;22:593–6.
132. , , , Micturitional disturbance in subacute myelo-optico-neuropathy (SMON). Auton Neurosci 2001;87:282–5.
133. , , , , Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 2009;66:274–5.
134. , , , Micturitional disturbance in a patient with neurosarcoidosis. Neurourol Urodyn 2000;19:273–7.
135. , , , et al. Urinary retention can be the sole initial manifestation of acute myelitis. J Neurol Sci 2006;251:110–2.
136. , , , et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007;68:1474–80.
137. , , , , Parainfectious conus myelitis. J Neurol Sci 1998;161:156–62.
138. , , Spinal schistosomiasis. J Clin Neurosci 2002;9:317–20.
139. , , , et al. Schistosomal myelopathy: urologic manifestations and urodynamic findings. Urology 2002;59:195–200.
140. , , , Urinary dysfunction in Brown-Sequard syndrome. Neurourol Urodyn 2001;20:661–7.
141. , , , Bladder dysfunction in subacute combined degeneration: a clinical, MRI and urodynamic study. J Neurol 2008;255:1881–8.